Canonical microRNA loss drives tumor development implicating therapeutic efficacy of enoxacin in angiosarcoma
RNA · 2026
DOI: 10.1261/rna.080706.125 ↗Kurz gefasst
Fachartikel in der Zeitschrift RNA, 2026. Verfasst von Bozhi Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47906, USA. Hauptthemen laut MEDLINE: MicroRNAs, Hemangiosarcoma, Enoxacin. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Angiosarcoma (AS) is a rare and aggressive tumor arising within the endothelium, characterized by a high metastatic rate and poor prognosis. Our prior work established that endothelial loss of Dicer1, a key enzyme in microRNA (miRNA) processing, drives AS formation in mice, indicating a tumor suppressive role for miRNAs in tumorigenesis. Here, we corroborated this hypothesis by generating a novel conditional knockout model targeting Dgcr8, a core component of the microprocessor complex required for pri-miRNA processing. Conditional deletion of Dgcr8 phenocopies Dicer1 loss, resulting in spontaneous AS formation and global loss of mature miRNAs. We further demonstrate that treatment with enoxacin (ENX), a repurposed antibiotic known to enhance miRNA processing, reduces viability, migration, and clonogenicity of AS cells. ENX increases the abundance of tumor-suppressive miRNAs and downregulates oncogenic pathways, including pathways related to cell cycle progression, angiogenesis, and cell migration. These results establish the essential role of miRNA biogenesis in suppressing AS and reveal a pharmacologically targetable vulnerability via ENX-mediated enhancement of miRNA expression in tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47906, USA.
- Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana 47906, USA.
- Department of Biochemistry and Computer Science, Purdue University, West Lafayette, Indiana 47906, USA.
- Department of Comparative Pathobiology, Purdue University, West Lafayette, Indiana 47906, USA.
- Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47906, USA hannaja@purdue.edu.
ORCID-Profile: Bozhi Liu, Ant Murphy, Annaleigh Benton, Lauren Gartenhaus, Juliana M Bronzini, Samuel Hartzler, Alejandra Romero Alzate, Nimod D Janson, Shyaman Jayasundara, Sagar Utturkar, Nadia A Lanman, Majid Kazemian, Jason A Hanna
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Liu, B., Murphy, A., Benton, A., Gartenhaus, L., Budka, W., Bronzini, J. M., Hartzler, S., Yates, M. E., Alzate, A. R., Janson, N. D., Jayasundara, S., Utturkar, S., Lanman, N. A., Kazemian, M., & Hanna, J. A. (2026). Canonical microRNA loss drives tumor development implicating therapeutic efficacy of enoxacin in angiosarcoma. RNA. https://doi.org/10.1261/rna.080706.125
Vancouver
Liu B, Murphy A, Benton A, Gartenhaus L, Budka W, Bronzini JM, et al. Canonical microRNA loss drives tumor development implicating therapeutic efficacy of enoxacin in angiosarcoma. RNA. 2026. doi:10.1261/rna.080706.125
BibTeX
@article{Liu2026,
author = {Liu, Bozhi and Murphy, Ant and Benton, Annaleigh and Gartenhaus, Lauren and Budka, William and Bronzini, Juliana M and Hartzler, Samuel and Yates, Madison E and Alzate, Alejandra Romero and Janson, Nimod D and Jayasundara, Shyaman and Utturkar, Sagar and Lanman, Nadia A and Kazemian, Majid and Hanna, Jason A},
title = {Canonical microRNA loss drives tumor development implicating therapeutic efficacy of enoxacin in angiosarcoma},
journal = {RNA},
year = {2026},
doi = {10.1261/rna.080706.125}
}
EUVIMED